2025-524192-24-00招募中1 期
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Regulatory affairs
Scientific
Samsung Bioepis Co. Ltd.
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP2024-511493-67-00Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts45
尚未招募
不适用
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCMetastatic Castration Resistant Prostate CancerjRCT203125073254
招募中
不适用
GNX1021-01Gastrointestinal cancerjRCT203126014164